Premium
Antidepressant therapy: benefits and risks in perspective
Author(s) -
Burrows Graham D.,
Norman Trevor R.,
Dennerstein Lorraine,
Davies Brian M.
Publication year - 1985
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1985.tb08074.x
Subject(s) - mianserin , nomifensine , dyscrasia , antidepressant , medicine , adverse effect , trazodone , intensive care medicine , pharmacology , psychiatry , anxiety , plasma cell , dopaminergic , dopamine , multiple myeloma
The introduction of second generation antidepressants, such as mianserin and nomifensine, was prompted by the desire to produce drugs which were safer, had fewer side‐effects and were faster acting than the tricyclics. A brief review of the data on mianserin and nomifensine is presented in relation to these aims. Some advantages for the new drugs can be claimed and the risks of severe adverse effects relating to blood dyscrasias in the case of mianserin, and fever in the case of nomifensine, appear outweighed by the therapeutic gains.